Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Acknowledgments We acknowledge the Danish Council for Indepe
2019-12-02

Acknowledgments We acknowledge the Danish Council for Independent Research (Grant no. 11-105250) and the Carlsberg Foundation (Grant no. 2011-01-0567) for funding this work. Introduction DNA is vital as a biological target to design diagnostic agents as well as therapeutic drugs. The recognitio
-
Deferoxamine mesylate Inhibition of DHODH is reflected by an
2019-12-02

Inhibition of DHODH is reflected by an antiproliferative effect on peripheral blood mononuclear Deferoxamine mesylate (PBMCs), which can be measured by the inhibitory effect on their phytohemagglutinin (PHA) stimulated growth. The test was performed as described in the reference. Data for few select
-
Defensins are one major class of antimicrobial cationic pept
2019-12-02

Defensins are one major class of antimicrobial, cationic peptides that are released from VAS2870 and imbedded in the mucus layer on mucosal surfaces [45]. They can be categorized into two major families; α- and β-defensins. In humans there are two α-defensin members, defensin 5 (HD5) and defensin 6
-
br Materials and Methods br Results br Discussion Mitochondr
2019-12-02

Materials and Methods Results Discussion Mitochondrion not only generates energy but also produces ROS under physiological conditions. However, overnutrition causes mitochondrial congestion and elicits excessive ROS generation, leading to insulin resistance (Muoio, 2014, Houstis et al., 200
-
A further quandary concerning rediscoveries arises
2019-12-02

A further quandary concerning rediscoveries arises in habitats modified and frequented by humans, where rediscovered species may occur through accidental or deliberate introductions (Metcalf et al., 2007) rather than having persisted despite adverse conditions. Confusion regarding origin could evoke
-
The classification of CK substrates
2019-12-02

The classification of CK2 substrates based on active enzyme subunit composition provides a framework for understanding the regulatory function of CK2β subunit. However, few experiments exist that functionally explore such classification [17], [18], [19], [20], [21], [22], [23]; this reflects practic
-
Ten non FH ADH probands fulfilled the
2019-12-02

Ten non-FH ADH probands fulfilled the diagnostic criteria of hyperabsorbers. Table 2 shows the main lipid characteristics of these subjects and of 10 non-hyperabsorber probands used for comparison. There were differences between groups in body mass index, waist circumference and triglycerides. Other
-
TgTCEA from petals TgTCEA and TgTCEB from pollen grains TgTC
2019-12-02

TgTCEA from petals (TgTCEA1) and TgTCEB from pollen grains (TgTCEB1) were used throughout the study. The recombinant enzymes were expressed in , and purified as the His-tag-free forms as described previously., Enzyme reactions were performed at 4 mM substrates under the same conditions as described
-
The AURA trial was a phase I
2019-12-02

The AURA trial was a phase I/II study evaluating the safety, tolerability and activity of Osimertinib in patients with EGFR-mutated NSCLC progressing after a previous EGFR TKI. The phase I component of the study included a dose escalation part (Osimertinib 20mg to 240mg), using a rolling six design,
-
nsc library br The classical ubiquitination pathway Ubiquiti
2019-12-02

The classical ubiquitination pathway Ubiquitination is an enzymatic process that involves the addition of an ubiquitin protein to a substrate that usually becomes inactivated followed by degradation in the proteasome; however, several other functions have also been described. For the discovery of
-
Although several examples of selective reduction
2019-11-30

Although several examples of selective have to happen to you of α-diazoesters to α-hydrazonoesters have been described in the literature, reports on practical and general examples of such a process are scarce. In this context, there was a need to devise a mild and general method for the selective re
-
Introduction Human cytomegalovirus CMV is a herpesvirus
2019-11-30

Introduction Human cytomegalovirus (CMV) is a herpesvirus which has a ubiquitous and worldwide distribution, and is the most frequent cause of congenital infection (Kenneson and Cannon, 2007). The prevalence is around 0.5–1% of all live births and is the leading cause of sensorineural hearing loss
-
br Significance Ubl post translational modifications are pot
2019-11-30

Significance Ubl post-translational modifications are potential targets for developing novel therapeutics for life-threatening diseases, such as c-Myc- and KRas-driven cancers that lack targeted therapy. However, only a few drugs are available to target these modifications. This lack of drugs hig
-
Our knowledge of DDR induced signaling pathways
2019-11-30

Our knowledge of DDR-induced signaling pathways is still fragmentary. In particular, we do not know which signaling effectors interact with the phosphorylated receptors and how different effectors are linked to the control of specific cellular functions. The DDRs are at the interface between RTKs an
-
The loss of secondary mutation T M mutation
2019-11-30

The loss of secondary mutation T790M mutation after AR and SCLC transformation was also reported for Rociletinib. Piotrowska et al. using the MGH NGS platform recently reported in 13 biopsies among 12 EGFR T790M+ patients progressing after treatment with Rociletinib the loss of EGFR T790M mutation i
16259 records 936/1084 page Previous Next First page 上5页 936937938939940 下5页 Last page